Angiotensin Converting Enzyme 2 News and Research

RSS

Neutralizing antibodies persist against SARS-CoV-2 at least a year after infection

Researchers in Finland have conducted a study showing that the neutralizing bodies generated following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – generally persist for at least a year.

19 Jul 2021

Dysbiosis in gut microbiota may cause severe secondary infection in COVID-19 patients

An interesting study led by scientists in the U.S. has recently revealed that the microbial community in the gut is directly affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and that virus-mediated gut microbiome dysbiosis may cause severe secondary infections in coronavirus disease 2019 (COVID-19) patients. The study is currently available on the bioRxiv* preprint server.

19 Jul 2021

Stronger and longer SARS-CoV-2 RBD-ACE2 binding associated with glycans in new study

A new study has been published on the bioRxiv* preprint server, which focuses on the mechanism behind the binding of SARS-CoV-2 with the host receptor, using a molecular dynamics approach. The authors of this study aim to highlight the role of glycans in initiating the interaction between S and ACE2.

19 Jul 2021

An assay capable of detecting SARS-CoV-2 antibodies in breast milk and other samples

In a recent study by US researchers (currently available on the medRxiv* preprint server), a specific immunoassay based on the spike glycoprotein’s receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is not only well suited for the detection of antibody response after infection and vaccination but may also represent a method of choice when conducting seroepidemiological studies.

19 Jul 2021

SARS-CoV-2 B.1.617 mutations L452 and E484Q do not work together to evade antibodies

A short report recently published in the Journal of Infectious Diseases demonstrates how spike mutations L452R and E484Q found in the variant B.1.617.1 of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) each confer modestly diminished sensitivity to Pfizer-BioNTech (BNT162b2) mRNA vaccine-elicited antibodies – with combined mutations having a similar impact as either one of them alone.

19 Jul 2021

Evaluation of a synthetic DNA SARS-CoV-2 vaccine INO-4800 using a nonhuman primate model

A new study published in Vaccine assesses the safety and efficacy of the synthetic DNA vaccine candidate INO-4800, delivered as a single or double dose regime.

18 Jul 2021

A drug candidate to prevent adverse reactions due to COVID-19 infection or vaccines

A new study describes the promising results of a new drug candidate in combating the illness caused by the binding of COVID-19-specific antibodies to infected cells.

18 Jul 2021

COVID-19 vaccine candidate that can be produced in yeast proves effective in macaques

Researchers in the United States have designed a modular protein subunit vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that elicited a strong immune response in macaques and prevented the animals from developing coronavirus disease 2019 (COVID-19).

15 Jul 2021

Short chain fatty acids have potential therapeutic applications against COVID-19, study suggests

SARS-CoV-2, the virus responsible for the COVID-19 pandemic, is highly transmissible, with nasal passages being the target of original infection.

15 Jul 2021

Should we be concerned about the SARS-CoV-2 Lambda variant?

As the coronavirus disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), wreaks havoc across the globe, the efficacy of available vaccines is being threatened by emerging variants.

15 Jul 2021

A pencil graphite biosensor that detects SARS-CoV-2

In a new study, scientists discuss the development of a rapid COVID-19 diagnostic tool known as the Low-cost Electrochemical Advanced Diagnostic (LEAD).

14 Jul 2021

New OMV-based COVID-19 vaccine candidate proves effective in mice

Researchers in Italy have demonstrated the efficacy of using modified outer membrane vesicles (OMVs) as a vaccine to protect against coronavirus disease 2019 (COVID-19) in an animal model.

14 Jul 2021

SARS-CoV-2 variants show distinct humoral response and transcriptional profiles in hamster model

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel, highly infectious respiratory virus, and the causative agent of coronavirus disease 2019 (COVID-19) pandemic. SARS-CoV-2, which first originated in Wuhan, in Hubei province of China, is a member of the Coronavirdae family and has a large, non-segmented RNA genome.

14 Jul 2021

Study identifies SARS-CoV-2 spike conformation exposing potential new therapeutic targets

Researchers in the United States have demonstrated that the viral spike protein used by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to infect host cells adopts an open conformation exposing novel epitopes that could serve as targets for therapeutic strategies to protect against coronavirus disease 2019 (COVID-19).

14 Jul 2021

Molecular dynamic analysis of SARS-CoV-2 inhibitors

A new study reports the results of molecular dynamic simulations that were performed in an effort to identify new drugs that could be effective against SARS-CoV-2.

13 Jul 2021

Neutralizing aptamers block SARS-CoV-2 infection in vitro

A new study describes the clinical utility of aptamers against SARS-CoV-2.

13 Jul 2021

Scientists develop mouse-specific SARS-CoV-2 strains that efficiently replicate in standard laboratory mice

A team of scientists in France recently developed a mouse-adapted strain of SARS-CoV-2 that efficiently replicates in the lungs of standard laboratory mice and induces mild to moderate disease. The study is currently available on the bioRxiv* preprint server.

13 Jul 2021

Review details clinical signs of SARS-CoV-2 infection in domestic and wild cats

Now, a new systematic review has been published in the journal Animals that focuses on the clinical symptoms in felines diagnosed with SARS-CoV-2 worldwide.

13 Jul 2021

Scientists identify novel entry receptors for SARS-CoV-2

Scientists from the Northeastern University, China, and University of Michigan, USA, have recently identified five potential entry receptors for SARS-CoV-2. These receptors specifically express in SARS-CoV-2-infected cells and have a high binding affinity for the viral spike protein.

12 Jul 2021

mRNA-based COVID-19 vaccine CV07050101 demonstrates limited immunogenicity in non-human primates

Scientists from the US and Germany have recently evaluated the efficacy of an mRNA-based COVID-19 vaccine candidate, CV07050101, in inducing humoral and cellular immune responses in non-human primates. The study reveals that prime-boost immunization with the vaccine candidate induces only limited immunity against SARS-CoV-2.

12 Jul 2021

Angiotensin Converting Enzyme 2 News and Research

Neutralizing antibodies persist against SARS-CoV-2 at least a year after infection

Dysbiosis in gut microbiota may cause severe secondary infection in COVID-19 patients

Stronger and longer SARS-CoV-2 RBD-ACE2 binding associated with glycans in new study

An assay capable of detecting SARS-CoV-2 antibodies in breast milk and other samples

SARS-CoV-2 B.1.617 mutations L452 and E484Q do not work together to evade antibodies

Evaluation of a synthetic DNA SARS-CoV-2 vaccine INO-4800 using a nonhuman primate model

A drug candidate to prevent adverse reactions due to COVID-19 infection or vaccines

COVID-19 vaccine candidate that can be produced in yeast proves effective in macaques

Short chain fatty acids have potential therapeutic applications against COVID-19, study suggests

Should we be concerned about the SARS-CoV-2 Lambda variant?

A pencil graphite biosensor that detects SARS-CoV-2

New OMV-based COVID-19 vaccine candidate proves effective in mice

SARS-CoV-2 variants show distinct humoral response and transcriptional profiles in hamster model

Study identifies SARS-CoV-2 spike conformation exposing potential new therapeutic targets

Molecular dynamic analysis of SARS-CoV-2 inhibitors

Neutralizing aptamers block SARS-CoV-2 infection in vitro

Scientists develop mouse-specific SARS-CoV-2 strains that efficiently replicate in standard laboratory mice

Review details clinical signs of SARS-CoV-2 infection in domestic and wild cats

Scientists identify novel entry receptors for SARS-CoV-2

mRNA-based COVID-19 vaccine CV07050101 demonstrates limited immunogenicity in non-human primates

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News